STAT+: Neurocrine Biosciences and the delicate balance of benefit and risk
STAT News · LC · trust 47/100
When it comes to rare disease treatments, patients often confront a difficult risk-benefit calculus. Such is the case with a therapy from Neurocrine Biosciences.
Read the original at STAT News →
Open in TruthVane →